TGFB1 and neoplasm: Targeting signaling pathways like TGF-β and Platelet-Derived Growth Factor (PDGF) that drive ASC-CAF differentiation also hold promise, potentially enhancing current treatments by disrupting CAF support within the tumor microenvironment (TME).